New radionuclide-based agent offers hope for treating a variety of cancers

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it

The FDA flashed a red light on Van­da Phar­ma­ceu­ti­cals’ ex­per­i­men­tal treat­ment for a gas­troin­testi­nal con­di­tion that dis­rupts the di­ges­tion process. The agency re­ject­ed tradip­i­tant in

Plus, news about Replim­mune, No­vo Nordisk and Bios­plice: Avid­i­ty Bio­sciences is look­ing for $300M in stock sale: The RNA com­pa­ny is plan­ning a $300 mil­lion